Scancell, PharmaJet sign agreement for melanoma vaccine delivery system

Source: LabPulse, September 2024

Clinical-stage biopharmaceutical company Scancell has signed a strategic partnership agreement with PharmaJet for the supply of PharmaJet’s needle-free Stratis delivery system for the delivery of Scancell’s advanced melanoma vaccine for both clinical development and commercial use.

The Stratis Intramuscular (IM) Needlefree Injection System has received U.S. Food and Drug Administration (FDA) 510(k) marketing clearance, the European Union’s CE Mark, and World Health Organization (WHO) prequalification to deliver medications and vaccines either intramuscularly or subcutaneously. Under the terms of the agreement, the Stratis system will be used to deliver Scancell’s Immunobody SCIB1/iSCIB1+ DNA vaccine.

The intramuscular delivery of the SCIB1/iSCIB1+ vaccine has demonstrated effective uptake of the DNA vaccine, Scancell said in a statement, with the potential to provide clinical benefit to patients with advanced and metastatic melanoma through allowing native cellular machinery to express the target antigen and induce a potent antitumor response.
READ THE ORIGINAL FULL ARTICLE